Replies to post #240287 on Biotech Values

[DewDiligence]

BHVN intranasal migraine drug bests placebo in second phase-3 trial—NDA expected in 1Q22:

https://www.prnewswire.com/news-releases/biohaven-reports-positive-topline-results-from-pivotal-migraine-trial-of-intranasal-zavegepant-demonstrating-ultra-rapid-pain-relief-by-15-minutes-prepares-for-submission-of-new-drug-application-301437767.html

[DewDiligence]

PFE owns 3% of BHVN as a consequence of the Nurtec deal announced in November (#msg-166695371):

https://finance.yahoo.com/news/biohaven-pfizer-complete-collaboration-transaction-120000871.html

[DewDiligence]

(PFE)—BHVN’s Nurtec ODT sold $190M in 4Q21 and $462M in full-year 2021:

https://www.prnewswire.com/news-releases/biohaven-announces-preliminary-4q2021-and-full-year-net-product-revenue-for-nurtec-odt-market-leading-novel-migraine-therapy-301455426.html

This is the migraine drug where PFE has ex-US commercial rights.

[DewDiligence]

PFE/BHVN—CHMP approves Rimegepant (a/k/a Nurtec ODT) for both chronic and episodic migraine:

https://finance.yahoo.com/news/biohaven-pfizer-receive-positive-chmp-115900434.html